Emily works on a range of contentious patent matters, focusing on the life sciences sector. She has advised on patent litigation in the UK High Court and Court of Appeal, as well as on pan-European and global patent litigation strategy, oppositions before the European Patent Office and pharmaceutical regulatory law.
She has experience of disputes relating to pharmaceuticals (small molecules and biologics), in vitro diagnostics and genetic testing. Typically the disputes on which Emily advises involve technically complex subject matter and large patent portfolios.
Emily’s recent experience includes advising:
- Gilead in the Patents Court and Court of Appeal in an action concerning the blockbuster Hepatitis C treatment, Sovaldi® and on other pan-European patent matters
- Ariosa on a multi-jurisdictional patent dispute concerning its Harmony® non-invasive prenatal genetic test, including a defence of patent infringement proceedings in the Patents Court
- Biogen, Roche and Genentech in a Patents Court action relating to MabThera®, a treatment for rheumatoid arthritis, follicular lymphoma and chronic lymphocytic leukaemia
- Biogen on a multi-jurisdictional patent dispute
- A global pharmaceutical company engaged in ICC proceedings concerning the termination of a co-promotion agreement in Japan
- Rising Star
Managing IP 2018
Emily graduated with a degree in Natural Sciences from Cambridge University, specialising in Neuroscience having studied a range of subjects including biochemistry, chemistry, cell biology and physiology. As an undergraduate, she carried out research projects at the Medical Research Council’s Mitochondrial Biology Unit in Cambridge, and at Cold Spring Harbor in the United States. In 2016 she was awarded a Distinction in the University of Oxford’s Postgraduate Diploma in Intellectual Property Law and Practice.
Emily is admitted as a solicitor in England & Wales and in Ireland. She is a junior member of AIPPI UK.